ArticleFrontiers in public health2025

Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China.

Rui Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.